ProPhase Labs, Inc. (PRPH)

↓ Download CSV

CIK 0000868278 · OTC · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, ProPhase Labs, Inc. reported revenue of $4.34M, down 35.8% from the prior year. The company ran a net loss, with a net margin of -339.3% and a gross margin of 31.9%. It held $59.87M in total assets against $56.36M in total liabilities.

Key ratios (FY2025)

31.9%
Gross margin
-415.4%
Operating margin
-339.3%
Net margin
-420.3%
Return on equity
-35.8%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$4.34M$6.77M$34.98M$122.65M$79.04M$14.51M$9.88M$13.13M$9.87M
Cost of Revenue$2.96M$6.92M$19.43M$51.99M$37.05M$9.91M$7.26M$8.35M$7.92M$3.21M
Gross Profit$1.38M-$150.0K$15.56M$70.65M$41.99M$4.61M$2.62M$4.78M$1.95M$997.0K
Operating Income-$18.05M-$38.63M-$21.22M$23.59M$9.80M-$2.08M-$3.24M-$1.63M-$3.99M-$2.66M
Net Income-$14.74M-$53.36M-$16.78M$18.46M$6.27M-$2.12M-$3.15M-$1.74M$40.59M-$2.87M
EPS (Diluted)$-1.74$-26.68$-0.98$1.17$0.41$-0.18$-0.27$-0.15$2.61$-0.17
Total Assets$59.87M$63.20M$91.93M$87.65M$89.30M$31.41M$12.27M$20.74M$33.66M$12.80M
Total Liabilities$56.36M$55.85M$42.54M$24.02M$30.67M$20.85M$1.04M$4.23M
Shareholders' Equity$3.51M$7.35M$49.38M$63.63M$58.63M$10.56M$11.23M$16.50M$31.85M$5.96M
Cash & Equivalents$90.0K$678.0K$1.61M$9.11M$8.41M$6.82M$434.0K$1.55M$3.17M$441.0K
Operating Cash Flow-$8.34M-$17.54M-$11.89M$28.55M-$13.62M-$2.59M-$841.0K-$2.12M-$2.84M-$472.0K
Capital Expenditures$0$906.0K$2.08M$3.92M$4.23M$1.69M$228.0K$140.0K
Shares Outstanding8.49M2.00M17.21M18.65M18.39M11.60M11.40M15.70M17.08M
Dividends Per Share$0.30$0.30